Fighting central nervous system disorders

Diseases of the central nervous system continue to catalyse dealmaking as companies search for new therapies to tackle some major unmet medical needs.

Praxis Precision Medicines, Inc. uses a genetics-driven approach to develop potential best-in-class drugs for patients with central nervous system (CNS) disorders that are characterized by faulty electrical activity in the brain.

Voyager Therapeutics is unlocking the potential of adeno-associated virus gene therapy to treat a range of neurological disorders, broadening the therapeutic window while ensuring efficacy and safety.

Gilgamesh Pharmaceuticals is developing a diverse portfolio of novel, potentially first-in-class and best-in-class medicines targeting mechanisms with demonstrated profound efficacy (onset duration and/or prolonged treatment duration) in humans for the treatment of mental health disorders.

PsychoGenics uses a high-throughput platform comprising cameras and AI to analyze the behaviors of mice given a drug candidate before comparing them to a reference database. The platform enables the development of novel neuropsychiatric drugs and accelerates drug discovery.